Early access
Sign in
Not yet taking people in NetherlandsPhase 2

Adding an anti-p40 antibody to lower side effects of combined immunotherapy in pleural mesothelioma

Tests whether an anti-p40 antibody reduces severe side effects of two immunotherapy drugs in mesothelioma.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Rotterdam, NetherlandsSee the site
Registry title
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in Mesothelioma
Status
Not yet recruiting
Phase
Phase 2
People taking part
42 people, planned
Started
3 Aug 2026
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
9 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pleural mesothelioma that cannot be removed by surgery and who can receive dual immune checkpoint treatment. It tests whether adding an anti-p40 antibody lowers severe side effects.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Pleural mesothelioma that cannot be removed by surgery, confirmed by histology or cytology.
Earlier treatment
No immunomodulatory drugs within 14 days before starting immune checkpoint treatment.

Main reasons for not taking part

  • Immunomodulatory drugs within 14 days before starting immune checkpoint treatment
  • Known hypersensitivity to ustekinumab
  • Active (mycobacterial) infection
  • Chronic, recurring infections

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • A diagnosis of pathologically confirmed irresectable pleural mesothelioma (confirmed by histology or cytology)
  • Age 18 years or older
  • ECOG performance status of 0 or 1, or a Karnofsky Performance Scale of 70 or higher
  • Eligible for dual ICB treatment

Who cannot take part

  • Current use of immunomodulatory drugs within 14 days prior to initiation of ICB
  • Known hypersensitivity to ustekinumab
  • Active (mycobacterial) infection
  • Chronic, recurring infections

Where in Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To evaluate whether co-administration of an anti-p40 antibody reduces the incidence of severe (grade ≥3) irAEs in patients receiving dual ICB with anti–PD-1 and anti–CTLA-4 antibodies.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma
Plain-language title
Adding an anti-p40 antibody to lower side effects of combined immunotherapy in pleural mesotheliomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
9 July 2026